Primary human mesothelioma cells express class II MHC, ICAM‐1 and B7–2 and can present recall antigens to autologous blood lymphocytes
暂无分享,去创建一个
B. Balbi | L. Mutti | P. Betta | E. Pozzi | A. Orengo | M. Valle | A. Lazzaro | P. Alciato | E. Gatti | P. Betta | Emiliano Gatti, | Ernesto Pozzi | Emiliano Gatti
[1] N. Hayashi,et al. Expression of costimulatory molecules B7‐1 (CD80) and B7‐2 (CD86) on human hepatocellular carcinoma , 1997, Hepatology.
[2] D. Fitzpatrick,et al. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. , 1996, Cancer research.
[3] T. H. van der Kwast,et al. EXPRESSION OF ICAM‐1 AND VCAM‐1 IN HUMAN MALIGNANT MESOTHELIOMA , 1996, The Journal of pathology.
[4] D. Fitzpatrick,et al. Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma. , 1996, Cancer letters.
[5] D. Fitzpatrick,et al. MOLECULAR PATHOBIOLOGY AND IMMUNOLOGY OF MALIGNANT MESOTHELIOMA , 1996, The Journal of pathology.
[6] N. Vogelzang,et al. Chemotherapy in malignant pleural mesothelioma. A review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Izbicki,et al. Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. , 1996, European journal of cancer.
[8] C. Smith,et al. Differential expression and release of CD54 induced by cytokines , 1995, Hepatology.
[9] R. Gusmano,et al. Antigen‐presenting function of human peritoneum mesothelial cells , 1995, Clinical and experimental immunology.
[10] C. Leong,et al. Biological and immunological aspects of malignant mesothelioma. , 1995, The European respiratory journal.
[11] J. Zeuthen,et al. A Human Melanoma Cell Line, Recognized by Both HLA Class I and Class II Restricted T Cells, is Capable of Initiating both Primary and Secondary Immune Responses , 1995, Scandinavian journal of immunology.
[12] W. J. Matthews,et al. Characteristics of nine newly derived mesothelioma cell lines. , 1995, The Annals of thoracic surgery.
[13] J. Peto,et al. Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.
[14] J. Gribben,et al. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.
[15] B. Robinson,et al. Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic mhc genes , 1994, International journal of cancer.
[16] J. Gribben,et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. , 1994, Blood.
[17] D. Fitzpatrick,et al. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. , 1994, Growth factors.
[18] L. Mutti,et al. Expression of intercellular adhesion molecule-1 (ICAM-1) by reactive mesothelial cells in pleural effusions. , 1993, Pathologica.
[19] N. Mavaddat,et al. An analysis of the relationship between γδ T cell receptor V gene usage and non‐major histocompatibility complex‐restricted cytotoxicity , 1993 .
[20] T. Whiteside,et al. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. , 1993, Clinical immunology and immunopathology.
[21] P. Astoul,et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. , 1993, Chest.
[22] B. Robinson,et al. HLA antigen expression and malignant mesothelioma. , 1991, American journal of respiratory cell and molecular biology.
[23] V. Rusch,et al. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. , 1991, The Journal of thoracic and cardiovascular surgery.
[24] F. Celada,et al. Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies , 1991, The Journal of experimental medicine.
[25] T. Ottenhoff,et al. Specific killing of cytotoxic T cells and antigen-presenting cells by CD4+ cytotoxic T cell clones. A novel potentially immunoregulatory T-T cell interaction in man , 1990, The Journal of experimental medicine.
[26] D. Ball,et al. The Treatment of Malignant Mesothelioma of the Pleura: Review of a 5‐Year Experience, With Special Reference to Radiotherapy , 1990, American journal of clinical oncology.
[27] R. Bowman,et al. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. , 1989, The American review of respiratory disease.
[28] T. Boon,et al. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis , 1983, The Journal of experimental medicine.
[29] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[30] L. Morasca. Effect of triazolium derivatives on the growth of tissue cultured cells. , 1965, European journal of cancer.